
The Korea Health Industry Development Institute (HIDI) and Korea Roche have created collaboration opportunities with local investment institutions in Switzerland and global pharmaceutical companies to support four domestic biotech firms in entering the European market. Following support for R&D costs and local relocation expenses, the plan is to expand the foundation for overseas commercialization through investment strategy training and meetings with executives at Roche's global headquarters.
HIDI announced on the 16th that it held a European market entry support program on the 12th in Basel, Switzerland, targeting companies selected under the "Korea Roche Korea-Switzerland BioPath" initiative, in collaboration with Korea Roche.
In April, HIDI signed a four-party memorandum of understanding with Korea Roche, the Basel Investment Agency, and the Technology Guarantee Fund to establish the BioPath program. The project links domestic biotech firms from R&D through the use of local infrastructure in Switzerland to financial support, with a total of four companies selected this year.
Ilumist Therapeutics and Survivorant Biologics, selected as recipients of research support, will each receive 100 million won in R&D funding. Ubicyst Therapeutics and iLab were selected as recipients of relocation support to the Innovation Park Basel (SIP) in Switzerland, with each company receiving 50 million won. Selected companies will also be provided with Roche global mentoring and customized guarantee support.
SIP is a biotech innovation hub located in Allschwil, near Basel, Switzerland, providing research and commercialization infrastructure such as laboratories, office space, and shared research facilities. Ubicyst Therapeutics and iLab plan to relocate there in the future to leverage the local biotech network.
During this program, expert presentations were held on topics including the establishment of local subsidiaries, investment attraction, and mergers and acquisitions (M&A) strategies. An official from the Basel Investment Agency introduced local market entry strategies, while Forty51 Ventures, a Swiss venture capital firm specializing in biotech, shared approaches to Series A and B funding and cooperation with overseas investment institutions.
In particular, a co-founder of T3 Pharmaceuticals, a Swiss biotech company acquired by Boehringer Ingelheim in 2023, introduced experiences ranging from startup formation to investment attraction, technology commercialization, and M&A.
The selected companies also visited Roche's global headquarters, where they met with key executives, including the head of the Global Pharmaceutical Business Division. They shared Roche's global open innovation strategy and partnership model, and discussed the potential for expanded cooperation with domestic biotech firms. The group also visited SIP, Biozentrum, a life sciences research institution at the University of Basel, and the Roche Institute for Human Biology.
Lee Hang-shin, head of the Industrial Promotion Division at HIDI, stated, "For domestic biotech companies to secure competitiveness in the global market, it is important to broaden their connections with overseas innovation ecosystems based on excellent technological capabilities." He added, "We expect this program to serve as an opportunity for domestic companies to deepen their understanding of the European market and discover new opportunities for global investment and technology cooperation."
HIDI plans to continue promoting collaboration programs to support the overseas expansion of domestic biotech firms through joint research with global pharmaceutical companies and global mentoring under "K-Biopharma NextBridge" in 2027.